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In MS lesions, perivascular activation of microglia colocalizes with areas of bloodbrain barrier (BBB) disruption (5) . Magnetic resonance imaging studies link BBB breakdown with clinical relapse (6) . Moreover, in vivo live imaging showed that BBB disruption provokes the immediate and focal activation of microglia (7) . However, the molecular mechanism that links BBB disruption with microglia activation and disease pathogenesis remains elusive. One of the earliest events coupled to BBB disruption in MS is leakage of the blood protein fi brinogen in the nervous system that results in perivascular deposition of fi brin (8) (9) (10) (11) . Although fi brinogen has been primarily studied for its functions
The fi brin-derived γ 377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease Multiple sclerosis (MS) is a chronic infl ammatory demyelinating disease of the nervous system in which an infl ammatory process is associated with destruction of myelin sheaths and later with axonal damage leading to permanent functional defi cits, such as paralysis and loss of vision (1) . Resident microglia are considered responsible for the eff ector mechanism leading to demyelination via their ability to phagocytose myelin and secrete proinfl ammatory cytokines (2) . Microglia are necessary not only for the maintenance but also for the onset of infl ammatory demyelination in central nervous system (CNS) autoimmune disease (3) , suggesting that attenuation of the microglia response could represent a promising therapeutic target for MS (2) . Although microglia represent a potentially in blood coagulation, there is appreciable evidence that fibrinogen plays a pivotal role in the infl ammatory response (12, 13) and host defense (14, 15) . Fibrinogen is a classic acute-phase reactant, characterized by a unique molecular structure with binding sites for cellular receptors that regulate the infl ammatory process (16, 17) . Research in MS animal models shows that prophylactic fi brin depletion either by genetic depletion of fi brinogen (18) or by prophylactic administration of anti-coagulants (18, 19) ameliorates disease pathogenesis. Although these studies show that prophylactic depletion of fi brin could be benefi cial in MS, the use of anti-coagulants would potentially have limited therapeutic value due to the hemorrhagic side eff ects after prolonged use of fi brin-depleting agents.
We sought to design a therapeutic strategy that would block the damaging eff ects of fi brinogen in the nervous system without aff ecting its benefi cial eff ects in blood coagulation by identifying and targeting the fi brinogen receptor in the nervous system. Impeding the interaction of fi brinogen with selected integrin receptors has been previously used as a strategy for drug development. Disruption of fi brinogen interaction with the platelet integrin receptor α IIb β 3 using either small molecule inhibitors or antibodies (e.g., ReoPro, abciximab) is highly eff ective at limiting thrombotic events in patients with vessel wall disease (20) . We hypothesized that if we identifi ed the specifi c cell type in the CNS responsive to fi brinogen and established the specifi c fi brinogen receptor used by these cells, we may be able to block the deleterious cellular responses associated with fi brin deposition in the nervous system without aff ecting its benefi cial coagulant properties.
Recent evidence showed that paralysis of CD11b + microglia ameliorates infl ammatory demyelination in the presence of peripheral T cells and macrophages (3) . CD11b is the α chain of the integrin receptor Mac-1 (α M β 2 , CD11b/ CD18) that in infl ammatory demyelination regulates phagocytosis of myelin (21, 22) . Myelin phagocytosis is thought to be subjected to modulation between inactive and active states of Mac-1 (23) . Immobilized fi brinogen and insoluble fi brin, but not soluble fi brinogen, have been identifi ed as physiological, high-affi nity ligands for Mac-1 (15, 24, 25) . Interestingly, in MS lesions fi brin deposition colocalizes with areas of activated microglia (11) . Here, we show that fi brinogen controls diff erentiation of microglia to phagocytes via the integrin receptor Mac-1. Moreover, a fi brinogen-derived peptide known to inhibit Mac-1 (γ 377-395 peptide) blocks microglia activation in vitro. Importantly, complementary in vivo studies using either the inhibitory γ 377-395 peptide or mice expressing a mutant form of fi brinogen lacking the Mac-1 binding motif establish that targeting the fi brin-Mac-1 interaction is a novel and potentially eff ective therapeutic strategy for infl ammatory demyelination. These studies show for the fi rst time that fi brin induces microglia activation and that targeting the infl ammatory but not the procoagulant properties of fi brinogen is suffi cient to suppress microglia activation and infl ammatory demyelinating disease.
RESULTS

Fibrinogen directly activates microglia resulting in cytoskeletal rearrangements and increased phagocytosis
We fi rst tested the eff ects of fi brinogen on pure primary microglia cells. Immobilized fi brinogen had a dramatic eff ect on microglia activation characterized by an increase in cell size ( Fig. 1 A, top right) when compared with untreated controls (Fig. 1 A, top left) . Quantitation revealed 85.5 ± 1.4% of activated microglia after fi brinogen treatment versus 8.2 ± 3.4% in untreated cells (Fig. 1 B; P < 0.001). In contrast to immobilized fi brinogen, soluble fi brinogen did not induce changes in microglia morphology (not depicted). LPS was used as a positive control (Fig. 1, A and B) . Using an endotoxin determination assay, we verifi ed that there was no LPS contamination in the fi brinogen-treated cultures. To assess the functional eff ect of this morphologic activation, we performed phagocytosis assays. Fibrinogen stimulation resulted in a 65.3% increase in phagocytosis as compared with untreated controls (P < 0.05), whereas LPS incubation, by comparison, increased phagocytosis by 39.1% (Fig. 1 C; P < 0.05). Previous studies have demonstrated that dynamic rearrangements of both the actin (26) and microtubule (27) networks are critical for phagocytosis. Deconvolution microscopy showed that fi brinogen stimulation resulted in dramatic rearrangement of the microglial cytoskeleton as determined by immunostaining of actin and β-tubulin (Fig. 1 D) . Collectively, these results suggest that fi brinogen induces microglia diff erentiation into a phagocytic state.
Fibrinogen activates microglia via the Mac-1 integrin receptor Mac-1 orchestrates the innate immune response by regulating phagocyte adhesion, migration, and engulfment of complement-opsonized particles (28) . M1/70, an antibody that blocks binding of fi brinogen to CD11b (24, 29) , inhibited fi brinogen-mediated microglia activation (Fig. 2 A) . Quantitation showed 71 ± 4.9% of activated microglia in fi brinogen-treated cells versus 18 ± 0.7% in cells treated with fi brinogen in the presence of M1/70 (Fig. 2 B ; P < 0.01). The inhibitory eff ect of M1/70 was specifi c for fi brinogen and did not aff ect LPS-mediated activation of microglia (Fig. 2 B) . Moreover, blocking CD11b reduced phagocytosis of fi brinogen-treated cells by 40% (Fig. 2 C ; P < 0.05). Previous studies have established that the Toll-like receptor (TLR)4 LPS receptor mediates LPS-induced microglia activation (30, 31) . In contrast, blocking TLR-4 did not aff ect fi brinogen-mediated phagocytosis, suggesting that Mac-1 was the major receptor to induce fi brinogen-mediated phagocytosis (Fig. 2 C) .
RhoA and phosphoinositide 3-kinase (PI3K) are the two major signaling pathways downstream of Mac-1 that mediate the cytoskeletal rearrangements for the induction of phagocytosis (28, 32, 33) . Fibrinogen induced a 1.9-fold increase of active RhoA and a 24-fold increase in Akt phosphorylation in microglia (Fig. 2 D) . Furthermore, blocking the PI3K signaling pathway using LY294002 inhibited the fi brinogeninduced increase of phagocytosis in microglia (Fig. 2 C ; P < 0.01), suggesting that PI3K is downstream of fi brinogenMac-1 signaling in microglia cells. This is the fi rst evidence suggesting that fi brinogen can induce Mac-1-dependent signaling in microglia.
Analysis of demyelinated spinal cords after the induction of proteolipid protein (PLP) 139-151 experimental autoimmune encephalomyelitis (EAE) in mice showed that CD11b + microglia ( Fig. 2 E, green) were surrounded by fi brin (Fig. 2 E,  red) . Similarly, analysis of acute demyelinating lesions of human MS showed that fi brin (Fig. 2 F, green) surrounded activated microglia cells (Fig. 2 F, red) . Collectively, these results show that fi brinogen/CD11b signaling induces phagocytosis in microglia and demonstrate both in EAE and in human MS the presence of this ligand-receptor system on active microglia within infl ammatory demyelinating lesions.
Fibrin depletion inhibits microglia activation in vivo and attenuates infl ammatory demyelination
We further examined whether fi brin is required for the activation of Mac-1 + cells in vivo. We administered the anticoagulant ancrod (34) in an established remitting-relapsing model of PLP 139-151 EAE (35) after the development of the fi rst paralytic incidence. At the time of the fi rst relapse, untreated mice show dramatic activation of CD11b + cells characterized by thick processes (Fig. 3 A, left, green) . In contrast, in ancrod-treated mice, CD11b + cells appear with ramifi ed morphology (Fig. 3 A, right, green) resembling CD11b + cells in the normal spinal cord (Fig. S1 , available at http://www .jem.org/cgi/content/full/jem.20061931/DC1). Single channel images are shown in Fig. S1 . Untreated mice showed extensive infl ammatory demyelinating lesions in the cerebellum (Fig. S2 , asterisk) and spinal cord (Fig. S2, arrows) . In contrast, in ancrod-treated mice, infl ammatory demyelination was dramatically decreased (Fig. S2 ). Ancrod treatment resulted in decreased demyelination by sevenfold in the cerebellum and by twofold in the spinal cord. Splenocytes isolated from untreated and ancrod-treated mice showed no diff erence in proliferation upon stimulation with PLP 139-151 ( Fig. S3) , further suggesting that CD11b + cells are the major cell target of fi brin in the nervous system. Fibrin-depleted mice recovered faster from the fi rst paralytic incidence and in contrast to control mice never relapsed (Fig. 3 B) . In a rotarod behavioral test performed before the fi rst relapse of the untreated group, fi brin-depleted mice showed a threefold increase of motor strength and coordination when compared with the untreated group (Fig. 3 C) . Control nonimmunized mice show values of ‫005ف‬ s on this assay. Collectively, these results suggest that fi brin is a major contributor to the local activation of CD11b + cells in vivo. In addition, this is the fi rst demonstration that an anti-coagulant may improve clinical symptoms and reduce infl ammatory demyelination when administered after the onset of paralytic symptoms. To examine the contribution of fi brinogen-Mac-1 signaling in vivo, we used mice with a knock-in mutation of seven amino acids at residues (N 390 RLSIGE 396 ) to alanine residues (A 390 AAAAAA 396 ) that abolishes fi brinogen binding to the Mac-1 receptor (15) . These mice, termed Fib 390-396A , show decreased Mac-1-mediated neutrophil adhesion resulting in decreased bacterial clearance (15) . Fib 390-396A and their age-and sex-matched littermate controls (Fib WT ) were backcrossed six generations to C57BL/6 background (15) and immunized with myelin oligodendrocyte glycoprotein (MOG) peptide (Fig. 4 A) . 
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molecule and is exposed only when fi brinogen is immobilized or converted to fi brin (25, 36) . We used 200 μM of peptide, a concentration shown to inhibit adhesion of Mac-1-overexpressing cells to immobilized fi brinogen (37) , to examine whether the γ 377-395 peptide could inhibit microglia activation. Fibrinogen treatment resulted in 71 ± 4.9% of activated microglia when compared with 38.3 ± 9.8% after the addition of the γ 377-395 peptide (Fig. 5 , A and B; P < 0.05), suggesting that the γ 377-395 peptide reduced fi brin-mediated microglia activation. The γ 377-395 peptide did not aff ect the activation state of untreated microglia and did not inhibit LPS-mediated microglia activation (Fig. 5 B) , further suggesting the specifi city of γ 377-395 to block the activation of Mac-1 by fi brin. In accordance, examination of Akt phosphorylation showed that the γ 377-395 peptide could specifi cally inhibit fi brin-mediated and not LPS-mediated phosphorylation of Akt (Fig. 5 C) . Overall, these results suggest that inhibition of fi brin-Mac-1 interactions by the γ 377-395 peptide inhibits both the morphological activation and the signaling cascade induced by fi brin-mediated activation of the Mac-1 microglia receptor.
Prophylactic or therapeutic administration of the fi brin 377-395 peptide suppresses EAE and inhibits microglia activation in vivo
Because genetic studies showed that the γ 377-395 binding epitope of fi brinogen to Mac-1 is not involved in coagulation (15) but is suffi cient to inhibit fi brin-mediated microglia activation (Figs. 4 and 5), we examined whether blocking exclusively the infl ammatory properties of fi brinogen in vivo using the γ 377-395 would be suffi cient to ameliorate EAE. We therefore examined the eff ects of in vivo administration of the γ 377-395 fi brin peptide on microglia activation and clinical progression in an animal model for MS. We fi rst assessed the eff ects of vaccination against γ 377-395 peptide. Vaccination with γ 377-395 peptide before the induction of EAE resulted in a signifi cant reduction in disease penetrance and clinical symptoms. All control mice (15/15) developed clinical symptoms of EAE. In contrast, only 53% of the vaccinated mice (8/15) developed EAE. Moreover, mice vaccinated with the γ 377-395 peptide showed an average clinical score of 1.1, whereas the control group showed a score of 2.5 (Fig. 6 A; P < 0.01). In a rotarod test, vaccinated mice showed a 76% increase in motor strength and coordination when compared with the control mice. Quantitative histopathological analysis showed reduced infl ammatory lesions in the cerebellum (index of 6.5 ± 5.9 vs. 12 ± 5.2; P < 0.05) and spinal cord (index of 1.5 ± 2 vs. 2.3 ± 1; P < 0.01) from γ 377-395 peptidevaccinated mice as compared with control mice.
Because vaccination is a preventive treatment, we further assessed whether γ 377-395 peptide would be benefi cial if administered after the onset of disease. We administered intranasally 30 μg γ 377-395 peptide daily after the fi rst paralytic episode in remitting relapsing EAE (35) . Intranasal delivery is a noninvasive delivery method that results in a higher degree of drug delivery to the nervous system and a lower degree of systemic drug delivery to tissues such as liver and lymph nodes when compared with intravenous delivery (38) . Intranasal delivery has been previously shown to be eff ective as a method of drug delivery in EAE (39) (40) (41) . γ 377-395 peptide-treated mice (n = 14) compared with control mice (n = 13) did not relapse (Fig. 6 B) . Peptide-treated mice showed a 1.4-fold increase of motor functions when compared with the control mice after the fi rst relapse on day 29. Administration of scramble peptide had no eff ect on the progression of EAE (Fig. S5 , available at http://www.jem .org/cgi/content/full/jem.20061931/DC1).
Immunohistochemical analysis using Mac-3, a microglia/ macrophage marker, revealed reduction of activated cells in the peptide-treated (Fig. 6 D) as compared with control animals (Fig. 6 C) . High magnifi cation images of Mac-3 immuno staining are shown in Fig. S6 , which is available at http://www.jem.org/cgi/content/full/jem.20061931/DC1. In addition, inducible nitric oxide synthase (iNOS), a major pro duct of activated CD11b + microglia in EAE (42) , was reduced in the γ 377-395 peptide-treated animals (Fig. 6 D, inset) .
Quantitation of the histopathological analysis shows reduction in both Mac-3 (P < 0.05) and iNOS (P < 0.01), whereas there are no major diff erences in T cell infi ltrates (Fig. 6 E ; P = 0.48). We further examined whether the γ 377-395 peptide aff ected the peripheral immune response. FACS analysis on the splenocytes of mice immunized with PLP 139-151 using six markers for peripheral immune cells, namely CD4 and CD8 T cells, CD11b macrophages, CD11c dendritic cells, and CD19 and B220 B cells, did not reveal any diff erences between untreated and γ 377-395 peptide-treated animals (Fig. S4) , suggesting that similar to systemic fi brin depletion (Fig. S3) , the γ 377-395 peptide does not aff ect the peripheral immune response. These results are in accordance with prior studies in which depletion of macrophages (43) Fibrinogen regulates blood coagulation by engaging the platelet α IIb β 3 integrin receptor via its γ 408-411 epitope, whereas it mediates infl ammatory processes by engaging the Mac-1 receptor via its γ 377-395 epitope. As a result, fi brinogen knockin mice, where the γ 390-396 Mac-1 binding site has been mutated, show normal coagulation properties, such as platelet aggregation, thrombus formation, and clotting time (15) . To determine whether the γ 377-395 peptide interfered with blood coagulation, we examined its eff ects on the procoagulant properties of fi brinogen both in vivo and in vitro. As expected, the γ 377-395 peptide does not aff ect coagulation in mice (Fig. 7 A) or prothrombin time (Fig. 7 B) . Moreover, in an in vitro fi brin polymerization assay, the γ 377-395 peptide did not alter the polymerization time of fi brin (Fig. 7 C) . In contrast, the GPRP peptide, an established inhibitor of clot formation (44) , inhibits fi brin polymerization (Fig. 7 C) . Collectively, these results show that in vivo delivery of the γ 377-395 peptide reduces the progression and severity of EAE by specifi cally targeting microglia/macrophage activation in the CNS parenchyma without adverse hemorrhagic eff ects.
DISCUSSION
In this study, we show for the fi rst time that inhibition of the infl ammatory but not the procoagulant properties of fibrinogen is suffi cient to suppress clinical symptoms and disease pathogenesis in an animal model of MS. We show that fi brinogen-Mac-1 interaction induces signal transduction pathways that support the activation of microglia and have identifi ed the fi brinogen γ 377-395 polypeptide that contains the Mac-1 binding motif as a therapeutic target for MS. Our study identifi es fi brinogen as a microglial activation signal and suggests the following model for the role of fi brin in infl ammatory demyelination (also see ARTICLE disruption, which precedes lesion development and clinical symptoms in MS (6, 45) , permits the leakage of fi brinogen perivascularly in the brain; (c) Fibrinogen is converted to fi brin either by cell-associated procoagulant factors (e.g., tissue factor) expressed within the nervous system or by bloodborne procoagulants (46); (d) Fibrinogen conversion to fi brin allows the exposure of the cryptic Mac-1 binding motif in fi brinogen associated with γ 377-395 sequence (25, 36) ; (e) Fibrin-Mac-1 interactions induce local activation of microglia, including a fi brin-dependent activation of Akt and Rho signaling, resulting in cytoskeletal rearrangements and increased phagocytic capacity; (f) Fibrin-mediated microglia activation events lead to local degenerative and phagocytic alterations that determine the extent of tissue damage in MS. Therefore, because fi brinogen within the CNS becomes appreciable only after injury or BBB disruption, it could serve as a matrix-associated "danger" signal and support infl ammatory processes. Given the colocalization of infl ammatory demyelinating lesions in MS with fi brin deposition, our data suggest that fi brinogen-Mac-1 interaction in the CNS parenchyma is central to microglia activation and determines the area of demyelination in MS.
Our study identifi es fi brinogen as a ligand for Mac-1 on microglia cells. Complement and in particular iC3b is well established as a ligand for Mac-1 (28) . The presence of immunoglobulins and activated complement is restricted to the pattern II MS lesions (1). Because microglia activation and phagocytosis are common features for all subtypes of MS, other factors in the demyelinating lesion could potentially mediate microglia activation. Because BBB disruption is a common feature for diff erent types of MS lesions, our study suggests that fi brin could serve as a broad activation signal for microglia in the CNS. Determination of the temporal and spatial distribution of the diff erent Mac-1 ligands in MS plaques would provide crucial information for the activation of these cells in diff erent disease stages. Activation of microglia contributes to both neuronal (47) and oligodendrocyte death (31) via release of cytokines and nitric oxide. The γ 377-395 peptide induced a reduction of iNOS + microglia, suggesting that inhibition of fi brin-Mac-1 interaction reduces microglia activation that in MS could mediate secondary damaging eff ects on other cell types of the nervous system.
Prior studies have shown that genetic ablation of CD11b + microglia (3) or antibodies against CD11b, such as M1/70 (48), reduce symptoms in EAE. The present studies further underscore the importance of Mac-1 in microglial activation in EAE, but establish that the interaction of Mac-1 with one specifi c ligand, the provisional matrix protein fi brinogen, is central to the clinical progression of disease and CNS pathologies. A genetic alteration in the endogenous fi brinogen γ chain gene that selectively eliminates the Mac-1 binding motif is suffi cient to ameliorate disease pathogenesis in EAE. Interestingly, mutating the Mac-1 binding motif on the fi brinogen γ chain does not aff ect either the clotting function of fi brinogen or the engagement of Mac-1 with other ligands (15) . Consistent with these fi ndings, pharmacologic disruption of fi brinogen-Mac-1 interaction with the fi brinogen-derived blocking γ 377-395 peptide (37) also strongly alleviated CNS disease and did not aff ect coagulation. For peptide-recognizing integrin receptors, such as the RGD-recognizing αvβ3 and α5β1 integrins, both the peptide itself and antibodies against the peptide may inhibit integrin-mediated biological eff ects (49) (50) (51) (52) . Similarly, the γ 377-395 peptide was found not only to directly block fi brinogen-Mac-1-dependent microglial activation events both in vitro (Fig. 5 ) and in vivo (Fig. 6, B-E) , but in addition, vaccination with the γ 377-395 peptide protects from EAE (Fig. 6 A) . One inference of this fi nding is that the generation of monoclonal antibodies against the γ 377-395 epitope could prove valuable therapeutic tools for MS.
Two previous studies have determined that pharmacologically depleting fi brinogen with snake venom-derived protease (ancrod) can prophylactically ameliorate symptoms of EAE (19, 53) . In this study, we further demonstrated that administration of ancrod can be benefi cial in limiting the clinical manifestations of EAE even after the onset of paralysis (Fig. 3 and Figs. S1 and S2). Although genetic or pharmacological depletion of fi brinogen illustrates the contribution of fi brinogen to infl ammatory demyelinating disease, the clinical value of suppression of coagulation with ancrod in the context of a chronic disease such as MS would depend upon the potential adverse hemorrhagic eff ects. The eff ective suppression of EAE observed in mice that either express a form of fully clottable fi brinogen that lacks the Mac-1 binding motif or were treated with the γ 377-395 peptide that has no anticoagulatant eff ects indicates that functional properties of fi brinogen can be therapeutically targeted without necessarily compromising hemostasis. More detailed dose and pharmacological studies focusing on the γ 377-395 peptide or small molecule mimetics will be necessary to reveal the potential eff ectiveness of this class of inhibitor in the treatment of infl ammatory demyelinating disease.
An interesting unresolved question is the importance of the fi brinogen platelet integrin receptor α IIb β 3 in the progression of MS. Notably, α IIb β 3 transcripts are present in chronic MS lesions (54), supporting prior evidence for the presence of platelets in infl ammatory demyelinating lesions (55) . The clinical benefi ts associated with the mutant form of fi brinogen expressed by Fibγ 390-396A mice are not likely to be due to any platelet-related process because these mice have been shown to support normal platelet aggregation in vitro and normal platelet thrombus formation in vivo (15) . However, the potential contribution of fi brin-α IIb β 3 interactions in disease pathogenesis in MS could be readily defi ned in available mice either lacking α IIb or expressing a mutant form of fibrinogen lacking the α IIb β 3 binding motif.
Fibrin-Mac-1-mediated activation of monocyte cells is well established (17) . Therefore, in addition to microglia act ivation, the γ 377-395 fi brin peptide could inhibit the local Neither dose affected blood clotting times. (C) In vitro fi brin polymerization was examined in the presence of the γ 377-395 peptide. GPRP, a known inhibitor of fi brin formation, signifi cantly attenuated fi brin formation, whereas the γ 377-395 peptide had no effect on fi brin polymerization. act ivation and possibly migration of peripheral macrophages in infl ammatory demyelination. Our study shows that fi brinogen depletion or treatment with the γ 377-395 peptide attenuates the clinical symptoms in EAE by primarily ameliorating the microglia/macrophage response without interfering with T cell activation. These results are in accordance with previous studies that have established that not only depletion of macrophages (43) or microglia (3) in EAE results in amelioration of clinical symptoms in the presence of functional T cell activation, but also that induction of monocyte and dendritic cell activation can lead to infl ammatory demyelination even in the absence of T cells (56) . In addition to CD11b, fi brinogen binds to the CD11c chain of the CD11c/CD18 integrin (57) . The γ 377-395 fi brin peptide blocks the binding of fi brinogen to both CD11b and CD11c integrins (36) . The CD11c + perivascular dendritic cells are responsible for the presentation of myelin antigens (58, 59) . Whether fi brinogen as a ligand for CD11c/CD18 could regulate the cross talk of dendritic cells with T cells in the perivascular space in infl ammatory demyelination remains to be resolved. This is of particular interest because recent studies demonstrated that microglia activation regulates leukocyte recruitment (60) . Because the γ 377-395 fi brin peptide blocks the binding of fi brin to both CD11b and CD11c integrins, it is possible that targeting the γ 377-395 epitope could diminish the activation of both parenchymal (CD11b + ) and dendritic (CD11c + ) microglia. More detailed studies will be required to establish whether fi brin aff ects the cross talk of microglia with cells that are damaged during infl ammatory demyelination (61), such as oligodendrocytes and neurons.
Our study has identifi ed the inhibition of fi brin-Mac-1 interactions as a novel strategy for the attenuation of the microglia/macrophage activation in the CNS. Histopathological studies in acute MS have identifi ed perivenous lesions that appear to be driven by activated microglia/macrophages sometimes in the absence of lymphocytes (62, 63) . Although the activation of microglia and macrophages plays a central role in the pathogenesis of MS (3, 4, 43, 63) , agents that inhibit the microglia/macrophage response have not been developed (64) . Although MS is a disease with profound lesion heterogeneity, BBB disruption and microglia activation are common features for the four diff erent subtypes of MS lesions (1). Therefore, targeting fi brin-Mac-1 interactions could be benefi cial in diff erent MS subtypes as a microglia-suppressive therapy and could be used in combinational therapies targeting other aspects of MS pathogenesis. In addition to MS, microglia activation is observed in a variety of neurodegenerative diseases characterized by BBB disruption, such as spinal cord injury, stroke, and Alzheimer's disease (16) . It is therefore possible that targeting fi brin-Mac-1 interactions could represent a strategy for inhibiting microglia activation in neurodegenerative diseases. Because blocking fi brin-Mac-1 interactions does not interfere with the physiological properties of fi brin in blood coagulation, this strategy could be applied in chronic diseases such as MS without hemorrhagic side eff ects.
MATERIALS AND METHODS
Animals. 6-wk-old female SJL/J and C57BL/6 mice were purchased from The Jackson Laboratory or Harlan Sprague Dawley. 6-wk-old female Fib 390-396A mice were generated from double heterozygous matings to produce homozygous Fib 390-396A mice (15) and Fib WT littermate mice as controls. Fib 390-396A mice were backcrossed six generations to C57BL/6 mice (15) . All experiments were approved by the University of California, San Diego, Institutional Animal Care and Use Committee. Systemic defi brinogenation. Mice were depleted of fi brinogen as described previously (65) . The pumps deliver 0.5 μl/hour; thus, the mice received 2.4 U ancrod/day. In control animals, buff er-fi lled mini-pumps were implanted. NaCl at a concentration of 3 mg/ml. Peptides were aliquoted as single doses and stored at −20°C. Mice were administered 5 μl peptide or 0.9% NaCl as a control in each nare daily using a P10 micropipettor (Gilson) beginning after the peak of the fi rst paralytic episode.
Induction of EAE. EAE was induced in
Histopathology. Histopathologic analysis and quantitation of infl ammation and demyelination in mouse tissue were performed on cryostat or paraffi n sections as described previously (67) . Sections were stained with hematoxylin/ eosin and luxol fast blue/nuclear red. Spinal cord sections were fi xed with 2% paraformaldehyde for 10 min at 4°C and immunostained with a sheep anti-fi brinogen antibody (1:200; US Biological), rat anti-CD11b (1:5; Chemicon), von Willebrand Factor (1:1,000; DakoCytomation), iNOS (polyclonal; 1:750; Chemicon), Mac-3 (rat anti-mouse; 1:200; BD Biosciences), and CNPase (monoclonal; 1:2,000; Sternberger Monoclonals). The infl ammatory index is defi ned by the average number of infl ammatory blood vessels per spinal cord cross section. 10-15 cross sections per animal were counted by two observers blinded to the genotypes of the mice. For the cerebellum, the number of cuff s was quantifi ed in two cerebellar sections per animal. To additionally analyze the CNS lesions, we counted Luxol Fast Blue/nuclear red-stained sections, and the relative proportions of demyelinated areas (percentage with SEM) were determined using an ocular morphometric grid as described previously (67) . For human MS, paraffi n-embedded material was obtained from the Archives of the Center for Brain Research, Medical University of Vienna. Double immunofl uorescence was performed with antibodies against CD68 and fi brin. Images were collected using an Axioplan 2 Zeiss microscope with an Axiocam HRc camera or were processed for confocal microscopy using Olympus and Zeiss confocal microscopes.
Rotarod behavior test. The rotarod assay was performed on a TSE RotaRod apparatus (TSE Technical and Scientifi c Equipment GmbH) as described previously (68) . Rotarod assays were conducted with a 350-s maximum time limit, and means were collected for at least three trials. Statistical calculations were made by using Student's t test.
Culture of primary microglia cells. Microglia were isolated from cultures of mixed cortical cells as described previously (69) . In brief, cortices from P1 mice were isolated and digested with trypsin (0.4%) for 20 min at 37°C. Cells from four pups were plated onto poly-D-lysine-coated 75 cm 2 tissue culture fl asks. The culture medium (DMEM, 10% heat-inactivated FBS, and 1% Pen/Strep) was changed on day 2. After 2-3 wk in culture, the microglia were removed by the addition of 12 mM lidocaine (Sigma-Aldrich) and orbital shaking (180 rpm) for 20 min at 37°C. The cells were centrifuged (350 g), and the pellet was resuspended in complete medium and plated onto poly-D-lysine-coated tissue culture dishes. Microglia cell cultures were >95% pure as determined with three diff erent markers, IsoB4, IBA-1, and CD11b. To immobilize fi brinogen, tissue culture dishes were incubated overnight with 50 μg/ml fi brinogen (Calbiochem) in 20 mM Tris, pH 7.5, and 0.1 M NaCl at 37°C for all fi brinogen treatments. To serve as positive controls, LPS (Sigma-Aldrich) was added to the media at 1 μg/ml. Phagocytosis assay. Phagocytosis assays were performed on both primary murine microglia and a murine microglia cell line (BV2). BV2 cells are an established cell line used to study microglia responses (47) . BV2 cells were routinely passaged in DMEM, 20% heat-inactivated FBS, and 1% Pen/Strep. Microglia phagocytosis was assessed using the Vybrant phagocytosis assay kit (Invitrogen) according to the manufacturer's recommendations. Microglia were cultured in 96-well plates at 5,000 cells/well for 36 h at 37°C. Blocking experiments included the addition of 1 μM LY294002 (Cell Signaling), 10 μg/ml rat anti-CD11b (eBioscience), 10 μg/ml rat anti-TLR4 (eBioscience), or 10 μg/ml rat IgG (Jackson ImmunoResearch Laboratories) to the media. Results were obtained from four separate experiments performed in triplicates. Statistical calculations were made by using Student's t test.
Morphometry. Primary microglia were used for all morphologic analysis. Cells were plated on coated fi brinogen or in the presence of LPS for 72 h. Microglia were fi xed with methanol and immunostained with Isolectin B4 (1:300; Sigma-Aldrich). Blocking experiments involved the daily administration of 10 μg/ml rat anti-CD11b (eBioscience), 10 μg/ml rat IgG (Jackson ImmunoResearch Laboratories), 200 μM γ 377-395 peptide, or 200 μM of scramble peptide. Results were obtained from six separate experiments performed in duplicates. 250 cells per condition were counted for each individual experiment. Activated microglia were quantitated as those cells >2,000 μm 2 . Images were collected using an Axioplan 2 Zeiss microscope with an Axiocam HRc camera and analyzed using the Axiovision 4.5 program (Carl Zeiss). Quantitation of cell area was performed using the Interactive Measurement feature of the Axiovision 4.5 program (Carl Zeiss MicroImaging, Inc.). Statistical calculations were made by using Student's t test.
Endotoxin detection assay. Fibrinogen samples were tested for contaminating endotoxins by a Limulus Amebocyte Lysate assay (E-TOXATE kit; Sigma-Aldrich). Fibrinogen-treated samples had undetectable endotoxin levels (<0.5 endotoxin units).
Immunoblots. Western blots were performed using standard protocols (65) . Microglia were serum-starved overnight and plated on fi brinogen or with LPS for 6 h. Lysates were electrophoresed on 4-12% gradient SDS-PAGE gels and probed with phospho and total Akt antibodies (1:1,000; Cell Signaling). RhoA activation was performed as described previously (70) . In brief, 2 × 10 7 microglia were plated on fi brinogen for 6 h or with LPS for 10 min. Cell lysates were incubated with GST-Rhotekin agarose beads (provided by J. Heller Brown, University of California, San Diego, San Diego, CA) for 45 min at 4°C. The beads were washed, resuspended in Laemmli sample buff er, and electophoresed on a 15% SDS-PAGE gel. Activated and total Rho were detected with mouse anti-RhoA (1:500; Santa Cruz Biotechnology, Santa Cruz Biotechnology, Inc.). Densitometry was performed using the National Institutes of Health (NIH) Scion Image software using three blots from three separate experiments.
Deconvolution microscopy. Fluorescent images were obtained as described previously (70) . Primary microglia were stimulated with fi brinogen as described above. Cells were immunostained with antibodies to total actin (1:100; Sigma-Aldrich) or β-tubulin (1:100; Sigma-Aldrich).
Isolation of mouse splenocytes and T cell proliferation assay. Spleens were removed from control and fi brin-depleted mice after the induction of PLP 139-151 EAE and washed in PBS. Spleens were mechanically dissociated with sterile blades and fi ltered through 70-μm nylon screens. Splenocytes were pelleted and washed with an erythrocyte lysing solution (Biolegend). Cells were washed twice with PBS, counted, and seeded at a density of 0.5 × 10 6 cells/96 wells. Cells from both control and fi brin-depleted mice were either untreated or stimulated with 20 μg/ml PLP 139-151 , and proliferation was assayed by BrdU incorporation (Roche Applied Sciences) according to the manufacturer's instructions.
FACS analysis.
Primary mouse splenocytes were isolated from control and γ 377-395 peptide-treated mice immunized with PLP 139-151 on day 29 after immunization. Cells were immunostained with antibodies to CD4, CD8, CD11b, CD11c, CD19, and B220 (1:100; Biolegend) and analyzed on a Becton Dickinson FACSCalibur fl ow cytometer.
Hematological analyses. Citrated plasma was prepared from mice administered intranasally 30 μg or 90 μg γ 377-395 peptide or saline control daily for 7 d. Plasma clotting times were measured by combining 10 μl of citrated plasma with 10 μl of 2U/ml bovine thrombin (Enzyme Research Laboratories) and 40 mM CaCl 2 in a weigh boat fl oating in a 37°C water bath. Time to clot was determined by mixing with a toothpick. Plasma thrombin times were established as described previously (15) . Fibrin polymerization was evaluated by standard turbidity assays using plasma. In brief, citrate plasma (diluted tenfold in 20 mM Hepes, pH 7.4, containing 0.15 M NaCl and 5 mM ε-amino caproic acid) was combined with bovine thrombin (fi nal concentration, 0.2 U/ml; Enzyme Research Laboratories) and Ca 2+ (10 mM), and OD 350 measurements were taken every 30 s.
Online supplemental material. Fig. S1 shows low power images of CD11b and fi brinogen double immunofl uorescence that demonstrates that fi brin depletion using ancrod decreases microglia activation in EAE. Fig. S2 shows Luxol Fast Blue staining that reveals that fi brin depletion using ancrod reduces demyelinating lesions in EAE. Fig. S3 shows that there is no diff erence in proliferation under untreated or PLP 139-151 -stimulated conditions between control and ancrod-treated mice subjected to PLP 139-151 EAE. Fig.  S4 shows FACS analysis of splenocytes using the markers CD4, CD8, CD11b, CD11c, CD19, and B220 that reveals that the γ 377-395 peptide has no signifi cant eff ect on peripheral immune cells compared with control. Fig.  S5 shows that a scramble γ 377-395 peptide has no eff ect on progression of EAE. Fig. S6 shows high power images of Mac3 immunostaining in the spinal cord of untreated and γ 377-395 peptide-treated mice after the induction of EAE. The online supplemental material is available at http://www.jem.org/ cgi/content/full/jem.20061931/DC1.
